Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View Item
  • Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21.

Thumbnail
View/Open
Accepted version (557.3Kb)
Publication Date
2016-08
ICR Author
Eeles, Rosalind
Kote-Jarai, Zsofia
Author
Teerlink, CC
Leongamornlert, D
Dadaev, T
Thomas, A
Farnham, J
Stephenson, RA
Riska, S
McDonnell, SK
Schaid, DJ
Catalona, WJ
Zheng, SL
Cooney, KA
Ray, AM
Zuhlke, KA
Lange, EM
Giles, GG
Southey, MC
Fitzgerald, LM
Rinckleb, A
Luedeke, M
Maier, C
Stanford, JL
Ostrander, EA
Kaikkonen, EM
Sipeky, C
Tammela, T
Schleutker, J
Wiley, KE
Isaacs, SD
Walsh, PC
Isaacs, WB
Xu, J
Cancel-Tassin, G
Cussenot, O
Mandal, D
Laurie, C
Laurie, C
Thibodeau, SN
Eeles, RA
Kote-Jarai, Z
Cannon-Albright, L
Type
Journal Article
Metadata
Show full item record
Abstract
Previous genome-wide association studies (GWAS) of prostate cancer risk focused on cases unselected for family history and have reported over 100 significant associations. The International Consortium for Prostate Cancer Genetics (ICPCG) has now performed a GWAS of 2511 (unrelated) familial prostate cancer cases and 1382 unaffected controls from 12 member sites. All samples were genotyped on the Illumina 5M+exome single nucleotide polymorphism (SNP) platform. The GWAS identified a significant evidence for association for SNPs in six regions previously associated with prostate cancer in population-based cohorts, including 3q26.2, 6q25.3, 8q24.21, 10q11.23, 11q13.3, and 17q12. Of note, SNP rs138042437 (p = 1.7e(-8)) at 8q24.21 achieved a large estimated effect size in this cohort (odds ratio = 13.3). 116 previously sampled affected relatives of 62 risk-allele carriers from the GWAS cohort were genotyped for this SNP, identifying 78 additional affected carriers in 62 pedigrees. A test for an excess number of affected carriers among relatives exhibited strong evidence for co-segregation of the variant with disease (p = 8.5e(-11)). The majority (92 %) of risk-allele carriers at rs138042437 had a consistent estimated haplotype spanning approximately 100 kb of 8q24.21 that contained the minor alleles of three rare SNPs (dosage minor allele frequencies <1.7 %), rs183373024 (PRNCR1), previously associated SNP rs188140481, and rs138042437 (CASC19). Strong evidence for co-segregation of a SNP on the haplotype further characterizes the haplotype as a prostate cancer predisposition locus.
URL
https://repository.icr.ac.uk/handle/internal/214
Collections
  • Genetics and Epidemiology
  • Radiotherapy and Imaging
Version of record
10.1007/s00439-016-1690-6
Subject
PRACTICAL consortium
International Consortium for Prostate Cancer Genetics
Research team
Oncogenetics
Language
eng
Date accepted
2016-05-26
License start date
2016-08
Citation
Human genetics, 2016, 135 (8), pp. 923 - 938

Browse

All of ICR repositoryICR Divisions & RM Clinical UnitsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.